Suven Life Sciences gets patents for anti-neuro degeneration molecule
New Delhi: Drug firm Suven Life Sciences has received one product patent each from Australia and the US for its molecule to be used in the treatment of neuro-degenerative diseases.
These patents are valid through 2032 and 2034, respectively, the drug maker said in a filing to the BSE.
These patents have been granted for Suven’s pipeline of molecules in the CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally, CEO Venkat Jasti said.
The molecules are being developed for the treatment of cognitive impairment associated with neuro-degenerative disorders such as Alzheimer’s disease, attention deficit hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia, Suven Life Sciences said.
The stock traded at Rs. 187.65 on the BSE, up 1.73 per cent from its previous close.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd